UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/558,205	11/25/2005	Peer Kirsch	MERCK-3110 1853		
	7590 08/09/200 TE ZELANO & BRA	EXAMINER			
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD.			WU, SHEAN CHIU		
SUITE 1400 ARLINGTON,	VA 22201	ART UNIT	PAPER NUMBER		
•		•	1756		
			MAIL DATE	DELIVERY MODE	
			08/09/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	on No.	Applicant(s)			
Office Action Summary		10/558,20	15	KIRSCH ET AL.			
		Examiner		Art Unit			
		/Shean C.	Wu/	1756			
Period fo	The MAILING DATE of this communication or Reply	appears on the	cover sheet with the c	orrespondence add	iress		
WHIC - Exter after - If NO - Failui Any r	CRTENED STATUTORY PERIOD FOR REI CHEVER IS LONGER, FROM THE MAILING sisions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory perior to reply within the set or extended period for reply will, by state eply received by the Office later than three months after the mand patent term adjustment. See 37 CFR 1.704(b).	DATE OF TH 1.136(a). In no evo iod will apply and wi tute, cause the app	IIS COMMUNICATION ant, however, may a reply be tim II expire SIX (6) MONTHS from lication to become ABANDONE!	N. nely filed the mailing date of this cor D (35 U.S.C. § 133).			
Status							
2a) <u>□</u> 3) <u>□</u>	Responsive to communication(s) filed on 25 This action is FINAL . 2b) To Since this application is in condition for allow closed in accordance with the practice under the practice und	his action is n wance except	on-final. for formal matters, pro		merits is		
Dispositi	on of Claims						
5)□ 6)⊠ 7)□	Claim(s) 1-12 is/are pending in the application 4a) Of the above claim(s) is/are without claim(s) is/are allowed. Claim(s) 1-12 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and	Irawn from co	·				
Applicati	on Papers		•				
10)	The specification is objected to by the Examement The drawing(s) filed on is/are: a) and a specificant may not request that any objection to the Replacement drawing sheet(s) including the control of the oath or declaration is objected to by the	accepted or b) the drawing(s) brection is requir	e held in abeyance. See ed if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CF	, ,		
Priority u	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ■ All b) ■ Some * c) ■ None of: 1. ■ Certified copies of the priority documents have been received. 2. ■ Certified copies of the priority documents have been received in Application No. ■ 3. ■ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
2) Notice	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date 11/25/05.		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Application/Control Number: 10/558,205

Art Unit: 1756

DETAILED ACTION

Page 2

1. Claims 9 and 11 provide for the use of the present compound and liquid crystal medium comprising the compound thereof, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 9 and 11 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Application/Control Number: 10/558,205

Page 3

Art Unit: 1756

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

- 3. Claims 1-12 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 7,189,440. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claimed compounds and composition comprising the compounds thereof are disclosed by US '440. See the formula I of claim1, particularly, the formula I6 in claim 3. Also, see the bottom two compounds on col.10 to the first four on col. 11 and first two on col. 13 of US '440.
- 4. Please provide the reference 005 cited in IDS filed 11/15/05 to complete the record.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to /Shean C. Wu/ whose telephone number is 571-272-1393. The examiner can normally be reached on 9:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Huff can be reached on 571-272-1385. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1756

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shean C Wu/ Shean C Wu Primary Examiner Art Unit 1756 Page 4

scw